SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 7 — Focused Visit (Care-plan review) — Calamity Jane — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientMartha Canary
Date of birth1856-05-01
IdentifiersMRN HR-NI008-SYN-TD; SSN (made up) 000-08-9532
Document date1901-06-22
AuthorRuth Ann Kessler, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Sixteen-week review after a two-day return to drinking. [S]

History of Present Illness

Ms. Canary returns six weeks after her ten-week review. Her third injection was due four weeks after the second, but she was away for ranch work and it was given four days late. On the two days before it, after a hard week, she drank about half a pint of whiskey each day. On the second day she called the peer recovery specialist, who met her the next morning and brought her to the nurse for the injection. She has had no alcohol in the three weeks since and had no shakes or sweats. She told us about it herself and was afraid we would be angry. Her mammogram at the mobile unit last week was normal. She is eating two or three meals a day. [S]

ElementDetail
AlcoholTwo days of drinking about four weeks ago, about half a pint a day; none in the three weeks since
NaltrexoneThird injection four days late; next due in four days
WithdrawalNone
MoodPHQ-9 5; GAD-7 5
MammogramNormal

Review of Systems

SystemResultFinding
ConstitutionalNegativeEnergy good; weight rising
GastrointestinalNegativeNo abdominal pain, vomiting or yellowing
NeurologicalNegativeNo tremor or confusion
PsychiatricPositiveAshamed of the lapse at first, now determined; no thoughts of suicide or self-harm

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Gabapentin 300 mg oral capsule on a written five-day schedule for alcohol withdrawal: 300 mg in the morning, 300 mg in the afternoon and 600 mg at bedtime for three days, then 300 mg twice daily on day four, 300 mg at bedtime on day five, then stop; dispensed for the five days onlyPer the written five-day scheduleOral route1901-03-02 to 1901-03-06completedS
Thiamine 100 mg by intramuscular injection once daily for three days, given in the clinic100 mg intramuscularly once daily for three daysIntramuscular route1901-03-02 to 1901-03-04completedS
Thiamine 100 mg oral tablet, one tablet dailyOne tablet dailyOral route1901-03-05activeS
Folic acid 1 mg oral tablet, one tablet dailyOne tablet dailyOral route1901-03-02activeS
Potassium chloride extended-release 20 mEq oral tablet, one tablet daily with food for five daysOne tablet daily with food for five daysOral route1901-03-02 to 1901-03-06completedS
Magnesium oxide 400 mg oral tablet, one tablet twice daily for two weeksOne tablet twice daily for two weeksOral route1901-03-02 to 1901-03-16completedS
Naltrexone 50 mg oral tablet, one tablet dailyOne tablet dailyOral route1901-03-09 to 1901-03-30completedS
Extended-release naltrexone 380 mg by deep intramuscular injection into the buttock every four weeks, given by the clinic nurse380 mg intramuscularly every four weeksIntramuscular route1901-03-30activeS
Amoxicillin 500 mg oral capsule, one capsule three times daily for five daysOne capsule three times daily for five daysOral route1901-03-23 to 1901-03-28completedS
Ibuprofen 400 mg oral tablet, one tablet with food every 8 hours as needed for tooth pain, for up to five daysOne tablet with food every 8 hours as needed, up to five daysOral route1901-03-23 to 1901-03-28completedS
Acetaminophen 500 mg oral tablet, one tablet every 6 hours as needed with the ibuprofen, no more than 2,000 mg a day, for up to five daysOne tablet every 6 hours as needed, no more than 2,000 mg a dayOral route1901-03-23 to 1901-03-28completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1901-06-22Body height165cmS
1901-06-22Body weight52.6kgS
1901-06-22Body mass index (BMI) [Ratio]19.3kg/m2S
1901-06-22Systolic blood pressure116mm[Hg]S
1901-06-22Diastolic blood pressure74mm[Hg]S
1901-06-22Heart rate72/minS
1901-06-22Respiratory rate16/minS
1901-06-22Body temperature36.6CelS
1901-06-22Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1901-06-22Hemoglobin [Mass/volume] in Blood13.1g/dL12-15.5 g/dLNormalS
1901-06-22MCV [Entitic mean volume] in Red Blood Cells by Automated count95fL80-100 fLNormalS
1901-06-22Platelets [#/volume] in Blood by Automated count21410*3/uL150-400 10*3/uLNormalS
1901-06-22Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
1901-06-22Potassium [Moles/volume] in Serum or Plasma4.2mmol/L3.5-5.1 mmol/LNormalS
1901-06-22Creatinine [Mass/volume] in Serum or Plasma0.66mg/dL0.59-1.04 mg/dLNormalS
1901-06-22Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1896)/1.73 sq M111mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1901-06-22Glucose [Mass/volume] in Serum or Plasma84mg/dL70-99 mg/dLNormalS
1901-06-22Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma31U/L10-35 U/LNormalS
1901-06-22Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L7-35 U/LNormalS
1901-06-22Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma58U/L5-40 U/LHighS
1901-06-22Albumin [Mass/volume] in Serum or Plasma3.9g/dL3.5-5 g/dLNormalS
1901-06-22Phosphatidylethanol [Mass/volume] in Blood64ng/mL<=20 ng/mLHighS
1901-06-22Liver stiffness by US.transient elastography6.8kPa<=8 kPaNormalS
1901-06-22Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S
1901-06-22Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]5{score}S

Physical Exam

Vital signs recorded on 1901-06-22; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 116/74, pulse 72; weight 52.6 kg, BMI 19.3
EyesNo scleral icterus
AbdomenSoft and non-tender; no ascites
NeurologicalNo tremor

Problems

ProblemClinical statusVerificationCodeProvenance
Alcohol use disorder, severe (nine of eleven DSM-5-TR criteria), daily drinking of about a pint of whiskey with heavier binges for many years; synthetic modern episode linked to her documented lifelong heavy drinkingactiveconfirmed F10.20S — Synthetic modern coding; DSM-5-TR severe alcohol use disorder maps to F10.20 when withdrawal is coded separately. Person-first language; not a claim about her real diagnosis.
Alcohol withdrawal, mild, at low risk of complications (PAWSS 3, CIWA-Ar 9 at intake; no past seizures or delirium tremens), managed as an outpatient with daily nurse checksresolvedconfirmed F10.230S — Synthetic withdrawal episode; resolved by the one-week visit.
Raised liver enzymes (AST 96, ALT 44, GGT 240 U/L) with a FIB-4 index of 3.93, above the cut point for possible advanced fibrosis; liver stiffness measurement plannedresolvedconfirmed R74.01S — Synthetic presenting finding; superseded when elastography and the clinical picture supported alcohol-associated steatotic liver disease.
Alcohol-associated steatotic liver disease, without cirrhosis: liver stiffness 9.6 kPa after four weeks without alcohol, falling enzymes, normal bilirubin, albumin, INR and plateletsactiveconfirmed K70.0S — Synthetic modern diagnosis made at the four-week visit.
Depressive symptoms during heavy drinking (PHQ-9 14, item 9 scored 0); whether they are alcohol-induced or an independent depression to be judged after two to four weeks without alcoholresolvedprovisional F32.AS — Synthetic provisional finding; resolved as the PHQ-9 fell to 5 after ten weeks without alcohol, consistent with alcohol-induced depressive symptoms. Not a claim about her real mood.
Daily chewing tobacco for many years; not ready to stop at intakeactiveconfirmed F17.220S — Synthetic modern coding anchored to the documented chewing tobacco.
Underweight (BMI 18.4) with poor food intake, low folate, magnesium and phosphate, and slightly low albuminactiveconfirmed R63.6S — Synthetic finding anchored to a contemporary impression of poor nutrition (R).
Housing instability: staying in a spare room at a friend's house, with nowhere to go if that ends; has stayed in shelters in past wintersactiveconfirmed Z59.811S — Synthetic social need anchored to her documented poverty and moves from town to town.
Food insecurity: often goes without meals at the end of the monthactiveconfirmed Z59.41S — Synthetic social need anchored to her documented poverty.
Periapical abscess of a lower left molar with facial swelling and low-grade fever, on naltrexone; treated without opioids, tooth removed at the dental clinic the next day; resolvedresolvedconfirmed K04.7S — Synthetic acute illness; not a historical claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
Self-managementDrinking since the last visit (her own account, day by day), cravings and triggersEvery visitCompleted todayTwo days of drinking about four weeks ago; none since
LaboratoryPEth, explained as part of care and not as a test of honestyAt baseline and about every one to two monthsCompleted today64 ng/mL, consistent with her account of two days of drinking
LaboratoryThiamine, folate and electrolytesThiamine before glucose and through recovery; electrolytes rechecked within a week if lowCompleted todayThiamine and folic acid continued; hemoglobin 13.1 g/dL, MCV 95 fL; sodium 139, potassium 4.2 mmol/L, creatinine 0.66 mg/dL, eGFR 111, glucose 84 mg/dL
Medication safetyMedicine for alcohol use disorder: adherence, side effects, opioid exposureEvery four weeks, on timeDeferredThe third injection was given four days late because she was away for work, and the two days of drinking came just before it. No lasting harm: she stopped within two days, had no withdrawal, and her liver tests and elastography improved. Corrective action: injections are booked on days she chooses, with a reminder call and a ride from the peer specialist
LaboratoryLiver enzymes on naltrexoneBaseline, within the first months of treatment, then periodicallyCompleted todayAST 31, ALT 24 U/L, normal; GGT 58 U/L
ImagingLiver fibrosis: FIB-4, transient elastography, albumin, INR, plateletsElastography when FIB-4 is above 2.67, repeated after months without alcoholCompleted todayLiver stiffness 6.8 kPa; albumin 3.9 g/dL; platelets 214; FIB-4 1.30
ExaminationWeight, meals and food accessEvery visitCompleted todayWeight 52.6 kg, BMI 19.3; two or three meals a day
SurveyDepression (PHQ-9) and anxiety (GAD-7) after two to four weeks without alcoholAt baseline, after two to four weeks without alcohol, then at least monthly while symptoms persistCompleted todayPHQ-9 5, item 9 scored 0; GAD-7 5; no low mood after the lapse
SurveySuicide-risk review, safety plan, firearm storage and the 988 Suicide & Crisis LifelineEvery visitCompleted todayNo thoughts of suicide or self-harm after the lapse; rifle stored; 988 in her phone
Self-managementPeer recovery support and mutual-help meetingsWeekly peer contact; meetings of her choiceCompleted todayWeekly calls; the peer specialist met her the morning after the lapse; a second weekly contact added
Self-managementHousing, food, income and health coverageEvery visitCompleted todayStill in her room; rent assistance renewed
Self-managementChewing tobaccoEvery visitCompleted todayCutting down; would like to try nicotine lozenges next month
Medication safetyNaloxoneReassess at every visitNot indicatedNo opioid use

Goal progress:

Immunizations given today: Hepatitis B vaccine (HepB-CpG), second of two doses [S]

Guideline basis: The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018); The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020); The Healthcare Professional's Core Resource on Alcohol (2026); Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases (2019); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)

Follow-up: Second hepatitis B dose given today. Naltrexone injection in four days at a nurse visit. Review in two months. Second hepatitis A dose in four months. Call the peer specialist, the clinic or 988 at any time. [S]